MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.
Buda
Gabriele
G
Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University, Pisa, Italy. ga.buda@libero.it
Martino
Alessandro
A
Maggini
Valentina
V
Orciuolo
Enrico
E
Galimberti
Sara
S
Gentile
Massimo
M
Morabito
Fortunato
F
Antognoni
Federica
F
Brunori
Marino
M
Barale
Roberto
R
Rossi
Anna Maria
AM
Petrini
Mario
M
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib